Drug profile · INN
encorafenib
BRAFTOVI
encorafenib (BRAFTOVI) is a serine/threonine-protein kinase b-raf inhibitor. Associated with Pierre Fabre Australia Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — encorafenib
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- ORAL
- Patents
- 0
- Programs
- 16
- Data quality
- 0.84
Quick answer
encorafenib (BRAFTOVI) is a serine/threonine-protein kinase b-raf inhibitor. Associated with Pierre Fabre Australia Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Serine/threonine-protein kinase B-raf inhibitor
Primary target: Serine/threonine-protein kinase B-raf
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
| PMDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is encorafenib?
encorafenib (BRAFTOVI) is a serine/threonine-protein kinase b-raf inhibitor. Associated with Pierre Fabre Australia Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for encorafenib?
BRAFTOVI is a marketed brand name for encorafenib. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of encorafenib?
encorafenib has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.